*From the Authors*:

Much of the recent debate on how to define bronchopulmonary dysplasia (BPD) has focused on identifying diagnostic criteria that adequately predict meaningful childhood outcomes ([@bib1]). The goal of our study group was to help inform this debate by providing an evidence-based definition of BPD that was chosen according to the ability to predict respiratory and neurodevelopmental outcomes at 18--26 months corrected age ([@bib2]). In a contemporary, multicenter cohort of very preterm infants, we found that stratification of disease severity based on the mode of respiratory support administered at 36 weeks postmenstrual age (PMA), irrespective of current or prior exposure to supplemental oxygen, discriminated best between infants with and without adverse early childhood outcomes ([@bib2]).

In separate letters, Bancalari and colleagues and Isayama and Shah stress that choosing contemporary diagnostic criteria for BPD will require compromise. We agree that a single definition of BPD is unlikely to serve all purposes. For example, the clinical and diagnostic information required to establish the underlying respiratory pathophysiology may differ from that used to predict the presence or absence of future respiratory morbidity. Nevertheless, we believe that our study provides valuable information on how best to define BPD in the current era.

To our knowledge, there are no widely available, uniformly applied, validated diagnostic tests that can precisely characterize the etiology of respiratory failure in preterm infants. Therefore, all commonly used definitions of BPD invoke clinical respiratory support---treatment with supplemental oxygen and, in some cases, the mode of respiratory support---as proxy measures of the underlying respiratory illness ([@bib3]). Bancalari and colleagues write that "inspired oxygen is the simplest and most sensitive indicator of the severity of respiratory failure and parenchymal lung disease." However, heterogeneity in oxygen administration is a noted limitation of the existing diagnostic criteria for BPD ([@bib1]). Moreover, supplemental oxygen is used to treat multiple cardiopulmonary diseases in preterm infants, including apnea, pneumonia, pulmonary hypoplasia, and pulmonary arterial hypertension. Certain characteristics of the administered respiratory support, such as the mean airway pressure, can also affect the level of supplemental oxygen required to achieve a target Sa~O~2~~ ([@bib4]). Our analysis considered several potential definitions of BPD that stratified infants based on treatment with supplemental oxygen at levels of \<30% versus ≥30%. We found that this additional information did not improve our ability to predict respiratory or neurologic outcomes, once we accounted for an infant's mode of respiratory support at 36 weeks PMA.

Bancalari and colleagues also suggest that our proposed definition would be improved by including an indicator of disease chronicity. Notably, we found that requiring exposure to supplemental oxygen for at least 28 days before 36 weeks PMA to establish a diagnosis of BPD did not improve the prognostic accuracy of the definition ([@bib2]). Whether diagnosing BPD using data collected over several days immediately before or after 36 weeks PMA would improve prediction of childhood outcomes is uncertain. Any benefit conferred by such data must be weighed against the burden of further data collection and possible variability in the application of more complex diagnostic criteria.

Isayama and Shah raise another key question, namely, at what PMA should BPD be diagnosed for the purpose of predicting future morbidity? The literature suggests that the optimal time point remains uncertain. Studies are inconsistent as to when, between 36 and 40 weeks PMA, a diagnosis of BPD best predicts early childhood outcomes ([@bib5]--[@bib7]). There is even variability within individual studies depending on which outcome is selected ([@bib5], [@bib6]). The data do consistently show, however, that diagnosing BPD at later PMAs results in an increase in specificity but a decrease in sensitivity for predicting future morbidity ([@bib5]--[@bib7]). This means that moving the diagnosis of BPD beyond 36 weeks PMA will make us more confident that infants with BPD will experience childhood respiratory morbidity. Conversely, this change will make us less certain that infants "without BPD" will survive and be free of respiratory illness. Isayama and Shah suggest that a compromise might be to *a priori* select the diagnostic criteria and assessment time point that best serve a project's stated goals. We agree that such decisions will require careful thinking. As part of this debate, we must consider the pros and cons of using one (albeit imperfect) definition across all research and clinical endeavors versus using multiple definitions that serve select diagnostic purposes.

We look forward to these important discussions and learning about new research that improves our understanding of the pathophysiology and heterogeneity of BPD. In the meantime, we believe that the evidence-based definition of BPD we identified in our analysis will aid in the care of contemporary very preterm infants and support trials investigating new therapies aimed at reducing pulmonary morbidity and preventing adverse long-term outcomes in this vulnerable population.
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